MCRT Webcast: Myeloma Genetics with Three Experts - July 25, 2020

Faith Davies, MBBCh, MRCP, MD, FRCPath, is a member of the faculty of the Department of Medicine at New York University Langone Health and Director of the Clinical Myeloma Program at the Perlmutter Cancer Center. She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Her focus is on the biology and treatment of myeloma with an emphasis on potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into individualized treatment in the clinical setting. Prior to joining NYU Langone Health, Dr. Davies was Deputy Director of the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS). She also served as Professor of Medicine and Director of the Phase I Clinical Trials Program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute. Dr. Davies came to UAMS in 2014 from the Institute of Cancer Research and the Royal Marsden Hospital, both in London. She earned her medical degree from the College of Medicine, University of Wales. She completed her general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.

Sikander Ailawadhi, MD, is a Professor of Medicine in the Division of Hematology/Oncology at the Mayo Clinic Florida located in Jacksonville, Florida. He is also the Lead for the International Cancer Center. Dr Ailawadhi's career focus includes the treatment of plasma cell disorders, multiple myeloma (MM), Waldenström's macroglobulinemia, and chronic lymphocytic leukemia (CLL). His research focuses on understanding the epidemiology and pathophysiology of these disorders; evaluating the benefit of various therapeutic strategies in different populations based on racial-ethnic and socioeconomic diversity; and developing novel therapeutics by means of conducting several regional and national clinical trials, such as clinical trials for novel drugs. Dr Ailawadhi has a special interest in understanding the disparities in care of cancer patients and their outcomes with a special focus on patients from different racial and ethnic backgrounds.